ARTICLE | Company News
FDA accepts OGS's Vevesca NDA
October 17, 2001 7:00 AM UTC
Oxford Glycosciences (LSE:OGS; OGSI) said the FDA has accepted for filing its NDA for Vevesca ( OGT 918) an oral N-butyldeoxynojirimycin glucosyltransferase inhibitor to treat Type 1 Gaucher disease. ...